1
|
Comi G, Dalla Costa G, Stankoff B, Hartung HP, Soelberg Sørensen P, Vermersch P, Leocani L. Assessing disease progression and treatment response in progressive multiple sclerosis. Nat Rev Neurol 2024; 20:573-586. [PMID: 39251843 DOI: 10.1038/s41582-024-01006-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/30/2024] [Indexed: 09/11/2024]
Abstract
Progressive multiple sclerosis poses a considerable challenge in the evaluation of disease progression and treatment response owing to its multifaceted pathophysiology. Traditional clinical measures such as the Expanded Disability Status Scale are limited in capturing the full scope of disease and treatment effects. Advanced imaging techniques, including MRI and PET scans, have emerged as valuable tools for the assessment of neurodegenerative processes, including the respective role of adaptive and innate immunity, detailed insights into brain and spinal cord atrophy, lesion dynamics and grey matter damage. The potential of cerebrospinal fluid and blood biomarkers is increasingly recognized, with neurofilament light chain levels being a notable indicator of neuro-axonal damage. Moreover, patient-reported outcomes are crucial for reflecting the subjective experience of disease progression and treatment efficacy, covering aspects such as fatigue, cognitive function and overall quality of life. The future incorporation of digital technologies and wearable devices in research and clinical practice promises to enhance our understanding of functional impairments and disease progression. This Review offers a comprehensive examination of these diverse evaluation tools, highlighting their combined use in accurately assessing disease progression and treatment efficacy in progressive multiple sclerosis, thereby guiding more effective therapeutic strategies.
Collapse
Affiliation(s)
- Giancarlo Comi
- Department of Neurorehabilitation Sciences, Casa di Cura Igea, Milan, Italy.
| | | | - Bruno Stankoff
- Sorbonne Université, Paris Brain Institute, Institut du Cerveau et de la Moelle Épinière, Centre National de la Recherche Scientifique, Inserm, Paris, France
| | - Hans-Peter Hartung
- Brain and Mind Center, University of Sydney, Sydney, Australia
- Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic
- Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
| | - Per Soelberg Sørensen
- Department of Neurology, Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
| | - Patrick Vermersch
- University of Lille, Inserm U1172, Lille Neuroscience & Cognition, Centre Hospitalier Universitaire de Lille, Fédération Hospitalo-Universitaire Precision Medicine in Psychiatry, Lille, France
| | - Letizia Leocani
- Vita-Salute San Raffaele University, Milan, Italy
- Multiple Sclerosis Center, Casa di Cura Igea, Milan, Italy
| |
Collapse
|
2
|
Yam C, Brownlee WJ, Prados Carrasco F, Toosy A, Ciccarelli O. Investigating colour vision and its structural correlates 15 years following a first demyelinating event. J Neurol Neurosurg Psychiatry 2024:jnnp-2024-334551. [PMID: 39266283 DOI: 10.1136/jnnp-2024-334551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Accepted: 08/27/2024] [Indexed: 09/14/2024]
Abstract
BACKGROUND We investigated the long-term colour and contrast vision outcomes, 15 years after a first demyelinating event, with their structural correlates using optical coherence tomography (OCT) and brain MRI. METHODS Patients recruited with their first demyelinating event, were invited~15 years later to undergo clinical assessments, OCT and brain MRI and were clinically classified according to multiple sclerosis (MS) phenotypes. Linear mixed models evaluated associations between visual outcomes, MS phenotypes and OCT measures. RESULTS 94 patients were evaluated after a median of 14.3 years. 111 eyes affected by optic neuritis and 77 unaffected eyes were studied. Optic neuritis eyes displayed worse colour vision than unaffected eyes. Unaffected eyes showed worse colour vision in relapsing-remitting MS and secondary progressive MS (SPMS) than clinically isolated syndrome, while no similar discriminatory ability was seen for OCT measures. However, ganglion cell inner plexiform layer (GCIPL) was superior to peripapillary retinal nerve fibre layer (pRNFL) in predicting all visual outcomes. Worse colour vision was associated with lower retinal thicknesses and higher brain T2 lesion load; adding MRI volumetrics to macular GCIPL predictors did not improve model prediction of visual outcomes. CONCLUSIONS Colour vision was impaired in unaffected eyes, especially in SPMS. GCIPL thinning underpinned this impairment more than pRNFL, suggesting neuroaxonal loss as the pathobiological substrate. The correlation between worse colour vision and increasing T2 lesion load suggests that colour dysfunction reflects overall greater disease burden. Quantitative evaluation of colour vision in addition to OCT may be useful to assess disease severity in patients after a first demyelinating event.
Collapse
Affiliation(s)
- Charmaine Yam
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, London, UK
| | - Wallace J Brownlee
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, London, UK
| | - Ferran Prados Carrasco
- Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK
| | - Ahmed Toosy
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, London, UK
| | - Olga Ciccarelli
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, London, UK
| |
Collapse
|
3
|
Cujbă L, Banc A, Stan C, Drugan T, Nicula C. Macular OCT's Proficiency in Identifying Retrochiasmal Visual Pathway Lesions in Multiple Sclerosis-A Pilot Study. Diagnostics (Basel) 2024; 14:1221. [PMID: 38928637 PMCID: PMC11202879 DOI: 10.3390/diagnostics14121221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 06/01/2024] [Accepted: 06/07/2024] [Indexed: 06/28/2024] Open
Abstract
Optical coherence tomography (OCT) is a non-invasive imaging technique based on the principle of low-coherence interferometry that captures detailed images of ocular structures. Multiple sclerosis (MS) is a neurodegenerative disease that can lead to damage of the optic nerve and retina, which can be depicted by OCT. The purpose of this pilot study is to determine whether macular OCT can be used as a biomarker in the detection of retrochiasmal lesions of the visual pathway in MS patients. We conducted a prospective study in which we included 52 MS patients and 27 healthy controls. All participants underwent brain MRI, visual field testing, and OCT evaluation of the thicknesses of the peripapillary retinal nerve fiber layer (pRNFL), macular ganglion cell layer (GCL), and macular inner plexiform layer (IPL). OCT measurements were adjusted for optic neuritis (ON). VF demonstrated poor capability to depict a retrochiasmal lesion identified by brain MRI (PPV 0.50). In conclusion, the OCT analysis of the macula appears to excel in identifying retrochiasmal MS lesions compared to VF changes. The alterations in the GCL and IPL demonstrate the most accurate detection of retrochiasmal visual pathway changes in MS patients.
Collapse
Affiliation(s)
- Larisa Cujbă
- Medical Doctoral School, University of Oradea, 410087 Oradea, Romania;
| | - Ana Banc
- Department of Ophthalmology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
| | - Cristina Stan
- Department of Ophthalmology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
| | - Tudor Drugan
- Department of Medical Informatics and Biostatistics, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
| | - Cristina Nicula
- Department of Maxillo-Facial Surgery and Radiology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania;
| |
Collapse
|
4
|
Ehrhardt H, Lambe J, Moussa H, Vasileiou ES, Kalaitzidis G, Murphy OC, Filippatou AG, Pellegrini N, Douglas M, Davis S, Nagy N, Quiroga A, Hu C, Zambriczki Lee A, Duval A, Fitzgerald KC, Prince JL, Calabresi PA, Sotirchos ES, Bermel R, Saidha S. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial. Neurology 2023; 101:e1014-e1024. [PMID: 37460235 PMCID: PMC10491449 DOI: 10.1212/wnl.0000000000207551] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 05/08/2023] [Indexed: 09/06/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Ganglion cell + inner plexiform layer (GCIPL) thinning, measured by optical coherence tomography (OCT), reflects global neurodegeneration in multiple sclerosis (MS). Atrophy of the inner (INL) and outer nuclear layer (ONL) may also be prominent in progressive MS (PMS). The phase 2, SPRINT-MS trial found reduced brain atrophy with ibudilast therapy in PMS. In this post hoc analysis of the SPRINT-MS trial, we investigate (1) retinal atrophy (2) differences in response by subtype and (3) associations between OCT and MRI measures of neurodegeneration. METHODS In the multicenter, double-blind SPRINT-MS trial, participants with secondary progressive MS (SPMS) or primary progressive MS (PPMS) were randomized to ibudilast or placebo. OCT and MRI data were collected every 24 weeks for 96 weeks. Extensive OCT quality control and algorithmic segmentation produced consistent results across Cirrus HD-OCT and Spectralis devices. Primary endpoints were GCIPL, INL, and ONL atrophy, assessed by linear mixed-effects regression. Secondary endpoints were associations of OCT measures, brain parenchymal fraction, and cortical thickness, assessed by partial Pearson correlations. RESULTS One hundred thirty-four PPMS and 121 SPMS participants were included. GCIPL atrophy was 79% slower in the ibudilast (-0.07 ± 0.23 µm/y) vs placebo group (-0.32 ± 0.20 µm/y, p = 0.003). This effect predominated in the PPMS cohort (ibudilast: -0.08 ± 0.29 µm/y vs placebo: -0.60 ± 0.29 µm/y, a decrease of 87%, p < 0.001) and was not detected in the SPMS cohort (ibudilast: -0.21 ± 0.28 µm/y vs placebo: -0.14 ± 0.27 µm/y, p = 0.55). GCIPL, INL, and ONL atrophy rates correlated with whole brain atrophy rates across the cohort (r = 0.27, r = 0.26, and r = 0.20, respectively; p < 0.001). Power calculations from these data show future trials of similar size and design have ≥80% power to detect GCIPL atrophy effect sizes of approximately 40%. DISCUSSION Ibudilast treatment decreased GCIPL atrophy in PMS, driven by the PPMS cohort, with no effect seen in SPMS. Modulated atrophy of retinal layers may be detectable in sample sizes smaller than the SPRINT-MS trial and correlate with whole brain atrophy in PMS, further highlighting their utility as outcomes in PMS. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that ibudilast reduces composite ganglion cell + inner plexiform layer atrophy, without reduction of inner or outer nuclear layer atrophy, in patients with primary progressive MS but not those with secondary progressive MS.
Collapse
Affiliation(s)
- Henrik Ehrhardt
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Jeffrey Lambe
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Hussein Moussa
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Eleni S Vasileiou
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Grigorios Kalaitzidis
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Olwen C Murphy
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Angeliki G Filippatou
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Nicole Pellegrini
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Morgan Douglas
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Simidele Davis
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Natalia Nagy
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Agustina Quiroga
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Chen Hu
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Alexandra Zambriczki Lee
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Anna Duval
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Kathryn C Fitzgerald
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Jerry L Prince
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Peter A Calabresi
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Elias S Sotirchos
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Robert Bermel
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH
| | - Shiv Saidha
- From the Department of Neurology (H.E., J.L., H.M., E.S.V., G.K., O.C.M., A.G.F., N.P., M.D., S.D., N.N., A.Q., C.H., A.Z.L., A.D., K.C.F., P.A.C., E.S.S., S.S.), Johns Hopkins University School of Medicine; Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD; and Mellen Center for Multiple Sclerosis (R.B.), Cleveland Clinic, OH.
| |
Collapse
|
5
|
Gernert JA, Böhm L, Starck M, Buchka S, Kümpfel T, Kleiter I, Havla J. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis. Int J Mol Sci 2023; 24:12872. [PMID: 37629053 PMCID: PMC10454007 DOI: 10.3390/ijms241612872] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 08/09/2023] [Accepted: 08/13/2023] [Indexed: 08/27/2023] Open
Abstract
The establishment of surrogate markers to detect disability progression in persons with multiple sclerosis (PwMS) is important to improve monitoring of clinical deterioration. Optical coherence tomography (OCT) could be such a tool. However, sufficient longitudinal data of retinal neuroaxonal degeneration as a marker of disease progression exist only for PwMS with a relapsing-remitting course (RRMS) so far. In contrast, longitudinal data of retinal layers in patients with primary-progressive MS (PPMS) are inconsistent, and the association of OCT parameters with ambulatory performance in PwMS has rarely been investigated. We aimed to investigate the relative annual rates of change in retinal layers in PwMS (RRMS and PPMS) compared with healthy controls (HC) using OCT and to evaluate their association with ambulatoryfunctionalscore (AS) worsening in PPMS. A retrospective analysis of a longitudinal OCT dataset of the retinal layers of PwMS and HC from two MS centers in Germany was performed. Walking ability was measured over a standardized distance of 500 m, and changes during the observation period were categorized using the AS and the expanded disability status scale (EDSS). 61 HC with 121 eyes and 119 PwMS (PPMS: 57 patients with 108 eyes; RRMS: 62 patients with 114 eyes) were included. The median follow-up time for PwMS was 3 years. The relative annual change of pRNFL (peripapillary retinal nerve fiber layer) and INL (inner nuclear layer) was significantly different in PwMS compared with HC. RRMS and PPMS subgroups did not differ in the annual atrophy rates. In patients with PPMS, worsening of the AS was significantly associated with increased thinning of the TMV (total macular volume), GCIP (ganglion cell and inner plexiform layer), and ONPL (outer nuclear and outer plexiform layer) (all p-value < 0.05, r > 0.30). For every -0.1% decrease in the TMV, GCIP, and ONPL, the risk of a deterioration in the AS increased by 31% (hazard ratio (HR): 1.309), 11% (HR: 1.112), and 16% (HR: 1.161), respectively. In addition, worsening EDSS in PPMS was significantly associated with the relative annual atrophy rates of pRNFL, TMV, and GCIP (all p-value < 0.05). Disability progression in PPMS can be measured using OCT, and increasing annual atrophy rates of the inner retinal layers are associated with worsening ambulation. OCT is a robust and side-effect-free imaging tool, making it suitable for routine monitoring of PwMS.
Collapse
Affiliation(s)
- Jonathan A. Gernert
- Institute of Clinical Neuroimmunology, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
| | - Luise Böhm
- Institute of Clinical Neuroimmunology, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
| | - Michaela Starck
- Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, 82335 Berg, Germany
| | - Stefan Buchka
- Institute of Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
| | - Tania Kümpfel
- Institute of Clinical Neuroimmunology, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
- Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, 82152 Planegg-Martinsried, Germany
| | - Ingo Kleiter
- Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, 82335 Berg, Germany
- Department of Neurology, Ruhr-University Bochum, 44791 Bochum, Germany
| | - Joachim Havla
- Institute of Clinical Neuroimmunology, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
- Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, 82152 Planegg-Martinsried, Germany
| |
Collapse
|
6
|
Cujba L, Stan C, Samoila O, Drugan T, Benedec Cutas A, Nicula C. Identifying Optical Coherence Tomography Markers for Multiple Sclerosis Diagnosis and Management. Diagnostics (Basel) 2023; 13:2077. [PMID: 37370972 DOI: 10.3390/diagnostics13122077] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 06/01/2023] [Accepted: 06/09/2023] [Indexed: 06/29/2023] Open
Abstract
BACKGROUND Multiple sclerosis (MS) is a common neurological disease affecting the optic nerve, directly or indirectly, through transsynaptic axonal degeneration along the visual pathway. New ophthalmological tools, arguably the most important being optical coherence tomography (OCT), could prove paramount in redefining MS diagnoses and shaping their follow-up protocols, even when the optic nerve is not involved. METHODS A prospective clinical study was conducted. In total, 158 eyes from patients previously diagnosed with relapsing remitting MS (RRMS)-with or without optic neuritis (ON), clinically isolated syndrome (CIS) with or without ON, and healthy controls were included. Each patient underwent an ophthalmologic exam and OCT evaluation for both eyes (a posterior pole analysis (PPA) and the optic nerve head radial circle protocol (ONH-RC)). RESULTS The macular retinal thickness (the 4 × 4, respectively, 2 × 2 grid) and thickness of the peripapillary retinal nerve fiber layer (pRNFL) were investigated. Various layers of the retina were also compared. Our study observed significant pRNFL thinning in the RRMS eyes compared to the control group, the pRNFL atrophy being more severe in the RRMS-ON eyes than the RRMS-NON eyes. In the ON group, the macular analysis showed statistically significant changes in the RRMS-ON eyes when compared only to the CIS-ON eyes, regarding decreases in the inner plexiform layer (IPL) thickness and inner nuclear layer (INL) on the central 2 × 2 macular grid. The neurodegenerative process affected both the inner retina and pRNFL, with clinical damage appearing for the latter in the following order: CIS-NON, CIS-ON, RRMS-NON, and RRMS-ON. In the presence of optic neuritis, SMRR patients presented an increase in their outer retina thickness compared to CIS patients. CONCLUSIONS To differentiate the MS patients from the CIS patients, in the absence of optic neuritis, OCT Posterior Pole Analysis could be a useful tool when using a central 2 × 2 sectors macular grid. Retinal changes in MS seem to start from the fovea and spread to the posterior pole. Finally, MS could lead to alterations in both the inner and outer retina, along with pRNFL.
Collapse
Affiliation(s)
- Larisa Cujba
- Medical Doctoral School, University of Oradea, 410087 Oradea, Romania
| | - Cristina Stan
- Department of Ophthalmology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
| | - Ovidiu Samoila
- Department of Ophthalmology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
| | - Tudor Drugan
- Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - Ancuta Benedec Cutas
- Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - Cristina Nicula
- Department of Ophthalmology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
| |
Collapse
|
7
|
Maier S, Barcutean L, Andone S, Manu D, Sarmasan E, Bajko Z, Balasa R. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. Int J Mol Sci 2023; 24:4375. [PMID: 36901807 PMCID: PMC10002756 DOI: 10.3390/ijms24054375] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 02/12/2023] [Accepted: 02/15/2023] [Indexed: 02/25/2023] Open
Abstract
Despite extensive research into the pathophysiology of multiple sclerosis (MS) and recent developments in potent disease-modifying therapies (DMTs), two-thirds of relapsing-remitting MS patients transition to progressive MS (PMS). The main pathogenic mechanism in PMS is represented not by inflammation but by neurodegeneration, which leads to irreversible neurological disability. For this reason, this transition represents a critical factor for the long-term prognosis. Currently, the diagnosis of PMS can only be established retrospectively based on the progressive worsening of the disability over a period of at least 6 months. In some cases, the diagnosis of PMS is delayed for up to 3 years. With the approval of highly effective DMTs, some with proven effects on neurodegeneration, there is an urgent need for reliable biomarkers to identify this transition phase early and to select patients at a high risk of conversion to PMS. The purpose of this review is to discuss the progress made in the last decade in an attempt to find such a biomarker in the molecular field (serum and cerebrospinal fluid) between the magnetic resonance imaging parameters and optical coherence tomography measures.
Collapse
Affiliation(s)
- Smaranda Maier
- Ist Neurology Clinic, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania
- Department of Neurology, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania
| | - Laura Barcutean
- Ist Neurology Clinic, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania
- Department of Neurology, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania
| | - Sebastian Andone
- Ist Neurology Clinic, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania
- Department of Neurology, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania
- Doctoral School, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania
| | - Doina Manu
- Center for Advanced Medical and Pharmaceutical Research, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania
| | - Emanuela Sarmasan
- Ist Neurology Clinic, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania
| | - Zoltan Bajko
- Ist Neurology Clinic, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania
- Department of Neurology, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania
| | - Rodica Balasa
- Ist Neurology Clinic, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania
- Department of Neurology, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania
- Doctoral School, ‘George Emil Palade’ University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania
| |
Collapse
|
8
|
Amirsadri M, Rahimi F, Khajepour A. Cost of Illness of Multiple Sclerosis in Isfahan, Iran, From a Social Perspective: A Comparison of the Human-Capital and Friction-Cost Methods. Value Health Reg Issues 2022; 30:26-30. [PMID: 35042020 DOI: 10.1016/j.vhri.2021.10.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 09/25/2021] [Accepted: 10/28/2021] [Indexed: 10/19/2022]
Abstract
OBJECTIVES Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that is characterized by demyelination and neurodegenerative changes and associated with high levels of disability. This study aimed to investigate direct and indirect costs of illness of patients with MS in Isfahan using and comparing human-capital and friction-cost methods from a societal perspective. METHODS A total of 300 patients with MS of 2 main centers of the disease in Isfahan, the MS center of Ayatollah Kashani hospital and Isfahan MS center, were included. Patient's demographic characteristics, disease information, and annual social costs (2018-2019) were collected using data collection form. Both the human-capital and friction-cost methods were applied and compared with value indirect costs because of loss of productivity. RESULTS From the social perspective, the average annual total cost of MS disease was estimated to be 1 441 163 710 rials (34 313 US dollar [USD]) per patient using the human-capital approach and 1 434 832 004 rials (34 162 USD) with the use of friction-cost method, from which 1 428 668 396 rials (34 016 USD) was related to direct costs. The main direct costs were related to disease-modifying therapies and referring to other physicians and hospitals. The cost of loss of production was greater with human-capital approach in comparison with friction-cost method. CONCLUSIONS The most prominent cost in MS disease is related to drug costs. The indirect costs were sensitive to the methods, applied in the study.
Collapse
Affiliation(s)
- Mohammadreza Amirsadri
- Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
| | - Farimah Rahimi
- Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Azin Khajepour
- Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
9
|
Yurtogullari S, Erbahceci IE. Inner and outer retina findings determined by optical coherence tomography in different subtypes of multiple sclerosis. Niger J Clin Pract 2022; 25:1069-1075. [DOI: 10.4103/njcp.njcp_1568_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Mehmood A, Ali W, Song S, Din ZU, Guo RY, Shah W, Ilahi I, Yin B, Yan H, Zhang L, Khan M, Ali W, Zeb L, Safari H, Li B. Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis. Brain Behav 2021; 11:e2302. [PMID: 34520634 PMCID: PMC8553325 DOI: 10.1002/brb3.2302] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 06/22/2021] [Accepted: 07/12/2021] [Indexed: 12/14/2022] Open
Abstract
This study explores the use of optical coherence tomography (OCT) to monitor and diagnose multiple sclerosis (MS). The analysis of reduced total macular volume and peripapillary retinal nerve fiber layer thinning are shown. The severity of these defects increases as MS progresses, reflecting the progressive degeneration of nerve fibers and retinal ganglion cells. The OCT parameters are noninvasive, sensitive indicators that can be used to assess the progression of neurodegeneration and inflammation in MS.
Collapse
Affiliation(s)
- Arshad Mehmood
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China
| | - Wajid Ali
- Key Laboratory of Functional Inorganic Materials Chemistry, School of Chemistry and Materials Science, Heilongjiang University, Harbin, P. R. China
| | - Shuang Song
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China
| | - Zaheer Ud Din
- Institute of Cancer Stem Cell, Dalian Medical University, Liaoning Province, P. R. China
| | - Ruo-Yi Guo
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China
| | - Wahid Shah
- Department of Physiology, Hebei Medical University, Shijiazhuang, Hebei, P. R. China
| | - Ikram Ilahi
- Department of Zoology, University of Malakand, Chakdara, Khyber Pakhtunkhwa, Pakistan
| | - Bowen Yin
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China.,Department of Neurology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, P. R. China
| | - Hongjing Yan
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China
| | - Lu Zhang
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China
| | - Murad Khan
- Department of Genetics, Hebei Key Lab of Laboratory Animal, Hebei Medical University, Shijiazhuang, Hebei Province, P. R. China
| | - Wajid Ali
- Green and Environmental Chemistry, Ecotoxicology and Ecology Laboratory, Department of Zoology, University of Malakand, Chakdara, Khyber Pakhtunkhwa, Pakistan
| | - Liaqat Zeb
- School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, P.R. China
| | - Hamidreza Safari
- Department of Immunology, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran
| | - Bin Li
- Department of Neurology, The Second Hospital of Hebei Medical University, City Shijiazhuang, Hebei Province, P. R. China.,Key Laboratory of Neurology of Hebei Province, City Shijiazhuang, Hebei Province, P. R. China
| |
Collapse
|
11
|
Guerrieri S, Comi G, Leocani L. Optical Coherence Tomography and Visual Evoked Potentials as Prognostic and Monitoring Tools in Progressive Multiple Sclerosis. Front Neurosci 2021; 15:692599. [PMID: 34421520 PMCID: PMC8374170 DOI: 10.3389/fnins.2021.692599] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 06/07/2021] [Indexed: 11/13/2022] Open
Abstract
Understanding the mechanisms underlying progression and developing new treatments for progressive multiple sclerosis (PMS) are among the major challenges in the field of central nervous system (CNS) demyelinating diseases. Over the last 10 years, also because of some technological advances, the visual pathways have emerged as a useful platform to study the processes of demyelination/remyelination and their relationship with axonal degeneration/protection. The wider availability and technological advances in optical coherence tomography (OCT) have allowed to add information on structural neuroretinal changes, in addition to functional information provided by visual evoked potentials (VEPs). The present review will address the role of the visual pathway as a platform to assess functional and structural damage in MS, focusing in particular on the role of VEPs and OCT, alone or in combination, in the prognosis and monitoring of PMS.
Collapse
Affiliation(s)
- Simone Guerrieri
- Experimental Neurophysiology Unit, San Raffaele Hospital, Institute of Experimental Neurology (INSPE), Milan, Italy.,Vita-Salute San Raffaele University, Milan, Italy
| | - Giancarlo Comi
- Vita-Salute San Raffaele University, Milan, Italy.,Casa di Cura del Policlinico, Milan, Italy
| | - Letizia Leocani
- Experimental Neurophysiology Unit, San Raffaele Hospital, Institute of Experimental Neurology (INSPE), Milan, Italy.,Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
12
|
Rzepiński Ł, Kucharczuk J, Maciejek Z, Grzybowski A, Parisi V. Spectral-Domain Optical Coherence Tomography Assessment in Treatment-Naïve Patients with Clinically Isolated Syndrome and Different Multiple Sclerosis Types: Findings and Relationship with the Disability Status. J Clin Med 2021; 10:jcm10132892. [PMID: 34209692 PMCID: PMC8268329 DOI: 10.3390/jcm10132892] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 06/25/2021] [Accepted: 06/26/2021] [Indexed: 01/08/2023] Open
Abstract
This study evaluates the peripapillary retinal nerve fiber layer (pRNFL) thickness and total macular volume (TMV) using spectral-domain optical coherence tomography in treatment naïve patients with the clinically isolated syndrome (CIS) and different multiple sclerosis (MS) types. A total of 126 patients (15 CIS, 65 relapsing-remitting MS, 14 secondary progressive MS, 11 primary progressive MS, 21 benign MS) with or without optic neuritis (ON) history and 63 healthy age-similar controls were assessed. Concerning controls' eyes, pRNFL thickness was significantly reduced in CIS-ON eyes (p < 0.01), while both TMV and pRNFL thickness was decreased in all MS eyes regardless of ON history (p < 0.01). Significant differences in pRNFL thickness and TMV between MS variants were observed for non-ON eyes (p < 0.01), with the lowest values in benign and secondary progressive disease type, respectively. The pRNFL thickness was inversely correlated with Expanded Disability Status Scale (EDSS) score in non-ON subgroups (p < 0.01), whereas TMV was inversely correlated with EDSS score in both ON and non-ON subgroups (p < 0.01). Concluding, pRNFL thinning confirms optic nerve damage in CIS-ON eyes and appears to be disproportionately high with respect to the disability status of benign MS patients. The values of TMV and pRNFL in non-ON eyes significantly correspond to MS course heterogeneity and patients' disability than in ON eyes.
Collapse
Affiliation(s)
- Łukasz Rzepiński
- Department of Neurology, 10th Military Research Hospital and Polyclinic, Powstańców Warszawy 5, 85-681 Bydgoszcz, Poland;
- Neurology Department, Sanitas—Neurology Outpatient Clinic, Dworcowa 110, 85-010 Bydgoszcz, Poland
- Correspondence:
| | - Jan Kucharczuk
- Department of Ophthalmology, 10th Military Research Hospital and Polyclinic, Powstańców Warszawy 5, 85-681 Bydgoszcz, Poland;
| | - Zdzisław Maciejek
- Department of Neurology, 10th Military Research Hospital and Polyclinic, Powstańców Warszawy 5, 85-681 Bydgoszcz, Poland;
- Neurology Department, Sanitas—Neurology Outpatient Clinic, Dworcowa 110, 85-010 Bydgoszcz, Poland
| | - Andrzej Grzybowski
- Department of Ophthalmology, University of Warmia and Mazury, Żołnierska 18, 10-561 Olsztyn, Poland;
- Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Mickiewicza 24/3B, 60-836 Poznan, Poland
| | | |
Collapse
|
13
|
Jakimovski D, Zivadinov R, Vaughn CB, Ozel O, Weinstock-Guttman B. Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. J Neurol Sci 2021; 427:117552. [PMID: 34175775 DOI: 10.1016/j.jns.2021.117552] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Revised: 06/18/2021] [Accepted: 06/19/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND Neurodegenerative changes in multiple sclerosis (MS) are associated with long-term disability progression (DP). Optical coherence tomography (OCT) measures may be used to monitor DP. OBJECTIVE To determine significant effects driving the changes in OCT-based peripapillary retinal nerve fiber layer (pRNFL) in heterogeneous group of MS patients. METHODS Total of 144 MS patients (109 relapsing-remitting MS and 35 progressive MS (PMS) with mean age at baseline of 47.6 and 56.5 years old, respectively) underwent clinical and OCT examination over 5-year follow-up. All OCT exams were reviewed using the OSCAR-IB criteria. The 5-year DP was determined based on Expanded Disability Status Scale (EDSS) changes and MS clinical trial criteria. Data regarding previous history of MS optic neuritis (MSON) and use of disease modifying treatment (DMT) was derived by in-person interview and review of electronic medical records. Mixed model-type of repeated measure analysis determined effects driving pRNFL change for analysis which utilized all eyes separately. RESULTS Over an average of 5.3-years follow-up, the MS population demonstrated significant pRNFL thinning (F = 16.108, p < 0.001). The pRNFL thinning was greater due to progressive MS subtype (F = 5.102, p = 0.025), greater age at baseline (F = 4.554, p = 0.034), occurrence of DP (F = 6.583, p = 0.011), and previous history of MSON (F = 7.053, p = 0.008). Use of any or highly potent DMT (natalizumab versus first-line injectable treatments versus no DMT) significantly reduced the pRNFL thinning (F = 8.367, p = 0.004) over the follow-up. Lastly, occurrence of DP in PMS patients older than 50 years old was associated with greater pRNFL thinning (F = 6.667, p = 0.013). CONCLUSION Longitudinal pRNFL changes are modified by age, disease subtype, disabiltiy progression, history of MSON, DMT use and their interactions.
Collapse
Affiliation(s)
- Dejan Jakimovski
- Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
| | - Robert Zivadinov
- Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York, Buffalo, NY, USA
| | - Caila B Vaughn
- Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA
| | - Osman Ozel
- Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA
| | - Bianca Weinstock-Guttman
- Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA
| |
Collapse
|
14
|
Baetge SJ, Dietrich M, Filser M, Renner A, Stute N, Gasis M, Weise M, Lepka K, Graf J, Goebels N, Hartung HP, Aktas O, Meuth S, Albrecht P, Penner IK. Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2021; 8:8/4/e1018. [PMID: 34045307 PMCID: PMC8161541 DOI: 10.1212/nxi.0000000000001018] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 04/13/2021] [Indexed: 01/04/2023]
Abstract
Objective Retinal layer thickness (RLT) measured by optical coherence tomography (OCT) is considered a noninvasive, cost-efficient marker of neurodegeneration in multiple sclerosis (MS). We aimed to investigate associations of RLT with cognitive performance and its potential as indicator of cognitive status in patients with MS by performing generalized estimating equation (GEE) analyses. Methods In this cross-sectional study, patients with at least mild signs of cognitive impairment were examined by OCT as well as by the Brief International Cognitive Assessment for MS and tests assessing attention and executive functions (Trail Making Test [TMT] A and B). Associations of these factors were investigated using GEE models controlling for demographic and disease-related factors and correcting for multiple testing. Results A total of 64 patients entered the study. In the final sample (n = 50 [n = 14 excluded due to missing data or drop-outs]; n = 44 relapsing-remitting MS and n = 6 secondary progressive MS, mean Expanded Disability Status Scale score = 2.59 [SD = 1.17], disease duration [median] = 7.34 [interquartile range = 12.1]), 36.0% were cognitively impaired. RLT of the macular retinal nerve fiber layer was associated with performance in TMT-B (β = −0.259). Analyses focusing on the upper and lower tertile of RLT additionally revealed associations between macular ganglion cell-inner plexiform layer and TMT-B and verbal short-term memory and learning, respectively. Conclusion In patients with MS, at less advanced disease stages, RLT was especially associated with cognitive flexibility promoting OCT as a potential marker advocating further extensive neuropsychological examination.
Collapse
Affiliation(s)
- Sharon Jean Baetge
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Michael Dietrich
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Melanie Filser
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Alina Renner
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Nathalie Stute
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Marcia Gasis
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Margit Weise
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Klaudia Lepka
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Jonas Graf
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Norbert Goebels
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Hans-Peter Hartung
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Orhan Aktas
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Sven Meuth
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Philipp Albrecht
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria
| | - Iris-Katharina Penner
- From the Cogito Center for Applied Neurocognition and Neuropsychological Research (S.J.B., M.F., A.R., N.S., I.-K.P.); Department of Neurology (M.D., M.G., M.W., K.L., J.G., N.G., H.-P.H., O.A., S.M., P.A., I.-K.P.), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), Department of Neurology, University of Sydney; and Department of Neurology (H.-P.H.), Medical University of Vienna, Austria.
| |
Collapse
|
15
|
Para-Prieto M, Martin R, Crespo S, Mena-Garcia L, Valisena A, Cordero L, Gonzalez Fernandez G, Arenillas JF, Tellez N, Pastor JC. OCT Variability Prevents Their Use as Robust Biomarkers in Multiple Sclerosis. Clin Ophthalmol 2021; 15:2025-2036. [PMID: 34025119 PMCID: PMC8132465 DOI: 10.2147/opth.s309703] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 04/08/2021] [Indexed: 11/23/2022] Open
Abstract
Objective To evaluate the agreement between the peripapillary retinal nerve fiber layer (pRNFL) and foveal thickness (FT) measurements among three different spectral domain-optical coherence tomography (SD-OCT) instruments in a sample of multiple sclerosis (MS) patients and a healthy age-matched control group. Methods An observational cross-sectional study with three groups: healthy subjects and MS patients w/w a previous clinical diagnosis of optic neuritis (ON) was conducted. The pRNFL and FT were measured using three different SD-OCT instruments (OCT PRIMUS 200 and OCT CIRRUS 500 SD-OCT [Carl Zeiss Meditec] and OCT 3D 2000 [Topcon]). Results Twenty eyes from 10 healthy subjects matched in age with MS patients without a previous history of eye disease and 62 MS eyes from 31 MS patients (29 eyes without history of ON and 33 eyes with history of ON) were enrolled. Healthy subjects and MS patients without ON did not show differences between the pRNFL and FT thickness (P>0.99) with any of the instruments. However, MS eyes with a previous episode of ON showed thinner pRNFL and FT (P<0.01). PRIMUS and CIRRUS OCT showed better agreement of the pRNLF and FT in both healthy and MS eyes. However, 3D OCT showed less agreement in the pRNFL measurement with CIRRUS in both healthy and MS eyes. Interpretation Although OCT is a valuable technology to improve MS patient assessment, differences between devices must be taken into account. It is necessary to create an international group that standardizes the measurement conditions and above all that provides reference bases for normal subjects.
Collapse
Affiliation(s)
- Marta Para-Prieto
- Universidad de Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA Eye Institute), Valladolid, 47011, Spain.,Hospital Clínico Universitario, Department of Ophthalmology, Valladolid, 47005, Spain
| | - Raul Martin
- Universidad de Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA Eye Institute), Valladolid, 47011, Spain.,Universidad de Valladolid, Departamento de Física Teórica, Atómica y Óptica, Valladolid, 47011, Spain.,Plymouth University, Faculty of Health and Human Sciences, Plymouth, UK
| | - Sara Crespo
- Hospital Clínico Universitario, Department of Ophthalmology, Valladolid, 47005, Spain
| | - Laura Mena-Garcia
- Universidad de Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA Eye Institute), Valladolid, 47011, Spain
| | - Andres Valisena
- Hospital Clínico Universitario, Department of Ophthalmology, Valladolid, 47005, Spain
| | - Lisandro Cordero
- Universidad de Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA Eye Institute), Valladolid, 47011, Spain
| | | | - Juan F Arenillas
- Hospital Clínico Universitario, Department of Neurology, Valladolid, 47005, Spain
| | - Nieves Tellez
- Hospital Clínico Universitario, Department of Neurology, Valladolid, 47005, Spain
| | - Jose Carlos Pastor
- Universidad de Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA Eye Institute), Valladolid, 47011, Spain.,Hospital Clínico Universitario, Department of Ophthalmology, Valladolid, 47005, Spain
| |
Collapse
|
16
|
Petzold A, Chua SYL, Khawaja AP, Keane PA, Khaw PT, Reisman C, Dhillon B, Strouthidis NG, Foster PJ, Patel PJ. Retinal asymmetry in multiple sclerosis. Brain 2021; 144:224-235. [PMID: 33253371 PMCID: PMC7880665 DOI: 10.1093/brain/awaa361] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 07/15/2020] [Accepted: 08/11/2020] [Indexed: 12/21/2022] Open
Abstract
The diagnosis of multiple sclerosis is based on a combination of clinical and paraclinical tests. The potential contribution of retinal optical coherence tomography (OCT) has been recognized. We tested the feasibility of OCT measures of retinal asymmetry as a diagnostic test for multiple sclerosis at the community level. In this community-based study of 72 120 subjects, we examined the diagnostic potential of the inter-eye difference of inner retinal OCT data for multiple sclerosis using the UK Biobank data collected at 22 sites between 2007 and 2010. OCT reporting and quality control guidelines were followed. The inter-eye percentage difference (IEPD) and inter-eye absolute difference (IEAD) were calculated for the macular retinal nerve fibre layer (RNFL), ganglion cell inner plexiform layer (GCIPL) complex and ganglion cell complex. Area under the receiver operating characteristic curve (AUROC) comparisons were followed by univariate and multivariable comparisons accounting for a large range of diseases and co-morbidities. Cut-off levels were optimized by ROC and the Youden index. The prevalence of multiple sclerosis was 0.0023 [95% confidence interval (CI) 0.00229–0.00231]. Overall the discriminatory power of diagnosing multiple sclerosis with the IEPD AUROC curve (0.71, 95% CI 0.67–0.76) and IEAD (0.71, 95% CI 0.67–0.75) for the macular GCIPL complex were significantly higher if compared to the macular ganglion cell complex IEPD AUROC curve (0.64, 95% CI 0.59–0.69, P = 0.0017); IEAD AUROC curve (0.63, 95% CI 0.58–0.68, P < 0.0001) and macular RNFL IEPD AUROC curve (0.59, 95% CI 0.54–0.63, P < 0.0001); IEAD AUROC curve (0.55, 95% CI 0.50–0.59, P < 0.0001). Screening sensitivity levels for the macular GCIPL complex IEPD (4% cut-off) were 51.7% and for the IEAD (4 μm cut-off) 43.5%. Specificity levels were 82.8% and 86.8%, respectively. The number of co-morbidities was important. There was a stepwise decrease of the AUROC curve from 0.72 in control subjects to 0.66 in more than nine co-morbidities or presence of neuromyelitis optica spectrum disease. In the multivariable analyses greater age, diabetes mellitus, other eye disease and a non-white ethnic background were relevant confounders. For most interactions, the effect sizes were large (partial ω2 > 0.14) with narrow confidence intervals. In conclusion, the OCT macular GCIPL complex IEPD and IEAD may be considered as supportive measurements for multiple sclerosis diagnostic criteria in a young patient without relevant co-morbidity. The metric does not allow separation of multiple sclerosis from neuromyelitis optica. Retinal OCT imaging is accurate, rapid, non-invasive, widely available and may therefore help to reduce need for invasive and more costly procedures. To be viable, higher sensitivity and specificity levels are needed.
Collapse
Affiliation(s)
- Axel Petzold
- Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery, London, UK.,UCL Queen Square Institute of Neurology, London, UK.,Dutch Expertise Centre for Neuro-ophthalmology and MS Centre, Departments of Neurology and Ophthalmology, Amsterdam UMC, Amsterdam, The Netherlands
| | - Sharon Y L Chua
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | - Anthony P Khawaja
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | - Pearse A Keane
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | - Peng T Khaw
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | - Charles Reisman
- Topcon Healthcare Solutions Research and Development, Oakland, New Jersey, USA
| | - Baljean Dhillon
- Centre for Clinical Brain Sciences, School of Clinical Sciences, NHS Lothian, Edinburgh, UK
| | - Nicholas G Strouthidis
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | - Paul J Foster
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | - Praveen J Patel
- NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
| | | |
Collapse
|
17
|
Ziccardi L, Barbano L, Boffa L, Albanese M, Grzybowski A, Centonze D, Parisi V. Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis. Front Neurol 2020; 11:858. [PMID: 33041959 PMCID: PMC7522220 DOI: 10.3389/fneur.2020.00858] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 07/07/2020] [Indexed: 11/13/2022] Open
Abstract
Purpose: To investigate on the morphology of the macular inner (IR) and outer (OR) layers in multiple sclerosis (MS) patients with and without history of optic neuritis (ON), followed by good or poor recovery of best corrected visual acuity (BCVA). Methods: Thirty-five normal control subjects and 93 relapsing remitting MS patients were enrolled. Of this, 40 MS patients without ON (MS-noON, 40 eyes), 27 with history of ON and good BCVA recovery (MS-ON-G, 27 eyes), and 26 with history of ON and poor BCVA recovery (MS-ON-P, 26 eyes) were studied. Controls and MS patients underwent an extensive ophthalmological examination including spectral-domain optical coherence tomography evaluating in 3 localized macular areas (0-1 mm, Area 1; 1-3 mm, Area 2; 3- 6 mm, Area 3), volumes (MV), and thicknesses (MT) of the whole retina (WR), further segmented in IR and OR. The differences of MV and MT between the groups were tested by ANOVA. In the MS-ON-P group, the correlations between MV and MT and BCVA were evaluated by Pearson's test. Results: When compared to controls, the MS-noON group showed not significantly (p > 0.01) different MVs, whereas MTs were significantly (p < 0.01) reduced in the evaluation of WR and IR. In the MS-ON-G group, a significant (p < 0.01) reduction of WR and IR MVs and MTs was found in Areas 2 and 3; OR MVs and MTs were similar (p > 0.01) to controls. In the MS-ON-P group a significant (p < 0.01) reduction of WR, IR, and OR MVs and MTs was detected in all areas; the BCVA reduction was significantly (p < 0.01) correlated with WR and IR MVs and MTs. Conclusions: In MS without history of ON or when ON is followed by a good BCVA recovery, the neurodegenerative process is limited to IR macular layers; in the presence of ON, with a poor BCVA recovery, a morphological impairment of both IR and OR macular layers occurs.
Collapse
Affiliation(s)
- Lucia Ziccardi
- Istituto di Ricovero e Cura a Carattere Scientifico - Fondazione Bietti, Rome, Italy
| | - Lucilla Barbano
- Istituto di Ricovero e Cura a Carattere Scientifico - Fondazione Bietti, Rome, Italy
| | - Laura Boffa
- Unit of Neurology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
| | - Maria Albanese
- Unit of Neurology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
| | - Andrzej Grzybowski
- Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland
- Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznan, Poland
| | - Diego Centonze
- Unit of Neurology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
- Istituto di Ricovero e Cura a Carattere Scientifico Neuromed - Unit of Neurology and Neurorehabilitation, Pozzilli, Italy
| | - Vincenzo Parisi
- Istituto di Ricovero e Cura a Carattere Scientifico - Fondazione Bietti, Rome, Italy
| |
Collapse
|
18
|
Yap TE, Balendra SI, Almonte MT, Cordeiro MF. Retinal correlates of neurological disorders. Ther Adv Chronic Dis 2019; 10:2040622319882205. [PMID: 31832125 PMCID: PMC6887800 DOI: 10.1177/2040622319882205] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Accepted: 09/20/2019] [Indexed: 12/11/2022] Open
Abstract
Considering the retina as an extension of the brain provides a platform from which to study diseases of the nervous system. Taking advantage of the clear optical media of the eye and ever-increasing resolution of modern imaging techniques, retinal morphology can now be visualized at a cellular level in vivo. This has provided a multitude of possible biomarkers and investigative surrogates that may be used to identify, monitor and study diseases until now limited to the brain. In many neurodegenerative conditions, early diagnosis is often very challenging due to the lack of tests with high sensitivity and specificity, but, once made, opens the door to patients accessing the correct treatment that can potentially improve functional outcomes. Using retinal biomarkers in vivo as an additional diagnostic tool may help overcome the need for invasive tests and histological specimens, and offers the opportunity to longitudinally monitor individuals over time. This review aims to summarise retinal biomarkers associated with a range of neurological conditions including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and prion diseases from a clinical perspective. By comparing their similarities and differences according to primary pathological processes, we hope to show how retinal correlates can aid clinical decisions, and accelerate the study of this rapidly developing area of research.
Collapse
Affiliation(s)
- Timothy E. Yap
- The Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London, UK
- The Imperial College Ophthalmic Research Group (ICORG), Imperial College London, UK
| | - Shiama I. Balendra
- Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, UK
| | - Melanie T. Almonte
- The Imperial College Ophthalmic Research Group (ICORG), Imperial College London, UK
| | - M. Francesca Cordeiro
- The Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London, NW1 5QH, UK
- The Imperial College Ophthalmic Research Group (ICORG), Imperial College, London, NW1 5QH, UK
- Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, 11–43 Bath Street, London, EC1V 9EL UK
| |
Collapse
|
19
|
Nally FK, De Santi C, McCoy CE. Nanomodulation of Macrophages in Multiple Sclerosis. Cells 2019; 8:cells8060543. [PMID: 31195710 PMCID: PMC6628349 DOI: 10.3390/cells8060543] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 05/31/2019] [Accepted: 06/03/2019] [Indexed: 12/16/2022] Open
Abstract
Multiple Sclerosis (MS) is a chronic demyelinating autoimmune disease primarily affecting young adults. Despite an unclear causal factor, symptoms and pathology arise from the infiltration of peripheral immune cells across the blood brain barrier. Accounting for the largest fraction of this infiltrate, macrophages are functionally heterogeneous innate immune cells capable of adopting either a pro or an anti-inflammatory phenotype, a phenomenon dependent upon cytokine milieu in the CNS. This functional plasticity is of key relevance in MS, where the pro-inflammatory state dominates the early stage, instructing demyelination and axonal loss while the later anti-inflammatory state holds a key role in promoting tissue repair and regeneration in later remission. This review highlights a potential therapeutic benefit of modulating macrophage polarisation to harness the anti-inflammatory and reparative state in MS. Here, we outline the role of macrophages in MS and look at the role of current FDA approved therapeutics in macrophage polarisation. Moreover, we explore the potential of particulate carriers as a novel strategy to manipulate polarisation states in macrophages, whilst examining how optimising macrophage uptake via nanoparticle size and functionalisation could offer a novel therapeutic approach for MS.
Collapse
Affiliation(s)
- Frances K Nally
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephen's Green, 2 D02 YN77 Dublin, Ireland.
| | - Chiara De Santi
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephen's Green, 2 D02 YN77 Dublin, Ireland.
| | - Claire E McCoy
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephen's Green, 2 D02 YN77 Dublin, Ireland.
| |
Collapse
|
20
|
Jankowska-Lech I, Wasyluk J, Palasik W, Terelak-Borys B, Grabska-Liberek I. Peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography in different clinical subtypes of multiple sclerosis. Mult Scler Relat Disord 2019; 27:260-268. [DOI: 10.1016/j.msard.2018.11.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2018] [Revised: 10/12/2018] [Accepted: 11/02/2018] [Indexed: 01/28/2023]
|
21
|
Coric D, Nij Bijvank JA, van Rijn LJ, Petzold A, Balk LJ. The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis. Neurodegener Dis Manag 2018; 8:323-335. [DOI: 10.2217/nmt-2018-0011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
In this review, a current overview is provided of how optical coherence tomography and infrared oculography can aid in assessing the visual system and CNS in multiple sclerosis (MS). Both afferent and efferent visual disorders are common in MS and visual complaints can have a tremendous impact on daily functioning. Optical coherence tomography and infrared oculography can detect and quantify visual disorders with high accuracy, but could also serve as quantitative markers for inflammation, neurodegeneration and network changes including cognitive decline in MS patients. The assessment of the efferent and afferent visual pathways is relevant for monitoring and predicting the disease course, but is also potentially valuable as an outcome measure in therapeutic trials.
Collapse
Affiliation(s)
- Danko Coric
- Department of Neurology, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands
| | - Jenny A Nij Bijvank
- Department of Neurology, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands
- Department of Ophthalmology, VU University Medical Centre, Amsterdam, The Netherlands
| | - Laurentius J van Rijn
- Department of Ophthalmology, VU University Medical Centre, Amsterdam, The Netherlands
| | - Axel Petzold
- Department of Neurology, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands
- Moorfields Eye Hospital & The National Hospital for Neurology & Neurosurgery, London, UK
| | - Lisanne J Balk
- Department of Neurology, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands
| |
Collapse
|
22
|
Abstract
AIMS This paper evaluates the impact of multiple sclerosis (MS) in Ireland, and estimates the associated direct, indirect, and intangible costs to society based on a large nationally representative sample. MATERIALS AND METHODS A questionnaire was developed to capture the demographics, disease characteristics, healthcare use, informal care, employment, and wellbeing. Referencing international studies, standardized survey instruments were included (e.g. CSRI, MFIS-5, EQ-5D) or adapted (EDSS) for inclusion in an online survey platform. Recruitment was directed at people with MS via the MS Society mailing list and social media platforms, as well as in traditional media. The economic costing was primarily conducted using a 'bottom-up' methodology, and national estimates were achieved using 'prevalence-based' extrapolation. RESULTS A total of 594 people completed the survey in full. The sample had geographic, disease, and demographic characteristics indicating good representativeness. At an individual level, average societal cost was estimated at €47,683; the average annual costs for those with mild, moderate, and severe MS were calculated as €34,942, €57,857, and €100,554, respectively. For a total Irish MS population of 9,000, the total societal costs of MS amounted to €429m. Direct costs accounted for just 30% of the total societal costs, indirect costs amounted to 50% of the total, and intangible or QoL costs represented 20%. The societal cost associated with a relapse in the sample is estimated as €2,438. LIMITATIONS AND CONCLUSIONS The findings highlight that up to 70% of the total costs associated with MS are not routinely counted. These "hidden" costs are higher in Ireland than the rest of Europe, due in part to significantly lower levels of workforce participation, a higher likelihood of permanent workforce withdrawal, and higher levels of informal care needs. The relationship between disease progression and costs emphasize the societal importance of managing and slowing the progression of the illness.
Collapse
Affiliation(s)
- Peter Carney
- a University College Dublin , Dublin , Ireland
- b Novartis Ireland , Dublin , Ireland
| | | | | | - Christopher McGuigan
- a University College Dublin , Dublin , Ireland
- d St. Vincent's University Hospital , Dublin , Ireland
| | - Killian O'Rourke
- a University College Dublin , Dublin , Ireland
- e Mater Hospital , Dublin , Ireland
| |
Collapse
|
23
|
Lambe J, Murphy OC, Saidha S. Can Optical Coherence Tomography Be Used to Guide Treatment Decisions in Adult or Pediatric Multiple Sclerosis? Curr Treat Options Neurol 2018; 20:9. [DOI: 10.1007/s11940-018-0493-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
24
|
Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis. Mult Scler Relat Disord 2018; 21:56-62. [PMID: 29459346 DOI: 10.1016/j.msard.2018.02.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2017] [Revised: 01/16/2018] [Accepted: 02/09/2018] [Indexed: 01/07/2023]
Abstract
BACKGROUND Multiple sclerosis is an inflammatory demyelinating disease characterized by progressive axonal loss affecting mainly the inner retinal layers. Optical coherence tomography (OCT) provides in-vivo quantification of the retinal layers and allows measuring progressive retinal changes. Our objective was to assess the longitudinal changes in the retina using spectral domain OCT (SDOCT) and to identify independent predictors affecting retinal thinning in MS patients. METHODS A prospective study in a tertiary care MS center was conducted to study the longitudinal retinal changes in MS patients. All subjects underwent baseline and follow up OCT assessment with segmentation analysis. Regression analysis was performed to assess clinical factors (age, sex, disease duration, history of optic neuritis before baseline, non-ocular clinical relapses) and MRI disease activity during the follow-up period. RESULTS The study included 102 MS patients with a mean follow-up duration of 3.9 ± SD years. At the last follow-up assessments, there were significant thinning of the average macular thickness (AMT) (p < .001), macular nerve fiber layer (MRNFL) (p < .001), ganglion cell-inner plexiform layer (GCIPL) (p < .001), and the peripapillary nerve fiber layer (PRNFL) (p < .001), compared to baseline. Early disease duration up to 10 years was associated with thinning of AMT, PRNFL, and GCIPL, while longer disease duration (> 15 years) was associated with only GCIPL thinning. Prior optic neuritis was predictive of more thinning of PRNFL (p = < .01), while MRI activity and female gender were significantly associated with more MRNFL thinning (p = < .01). CONCLUSION MS is associated with longitudinal thinning affecting AMT inner retinal layers (MRNFL, GCIPL, PRNFL). Early disease duration, female gender, MRI activity, and prior optic neuritis were predictive of faster rate of neuro-axonal loss. This may have implications in the design of future therapeutic trials.
Collapse
|
25
|
Kucharczuk J, Maciejek Z, Sikorski BL. Optical coherence tomography in diagnosis and monitoring multiple sclerosis. Neurol Neurochir Pol 2017; 52:140-149. [PMID: 29395116 DOI: 10.1016/j.pjnns.2017.10.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Revised: 10/16/2017] [Accepted: 10/17/2017] [Indexed: 10/18/2022]
Abstract
This paper presents application of optical coherence tomography (OCT) for diagnosis and monitoring of multiple sclerosis (MS). The peripapillary retinal nerve fibre layer thinning and the reduced total macular volume analysis are shown. With the course of the MS, the severity of these abnormalities increases which reflects the progressive degeneration of retinal ganglion cells and nerve fibres. The OCT parameters are sensitive, non-invasive indicators useful in assessing the progression of inflammation and neurodegeneration in MS.
Collapse
Affiliation(s)
- Jan Kucharczuk
- Department of Ophthalmology, 10th Military Research Hospital with Polyclinic, Bydgoszcz, Poland
| | - Zdzisław Maciejek
- Department of Neurology, 10th Military Research Hospital with Polyclinic, Bydgoszcz, Poland
| | - Bartosz L Sikorski
- Department of Ophthalmology, Nicolaus Copernicus University, Bydgoszcz, Poland.
| |
Collapse
|
26
|
Yadav SK, Motamedi S, Oberwahrenbrock T, Oertel FC, Polthier K, Paul F, Kadas EM, Brandt AU. CuBe: parametric modeling of 3D foveal shape using cubic Bézier. BIOMEDICAL OPTICS EXPRESS 2017; 8:4181-4199. [PMID: 28966857 PMCID: PMC5611933 DOI: 10.1364/boe.8.004181] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 07/26/2017] [Accepted: 07/27/2017] [Indexed: 06/07/2023]
Abstract
Optical coherence tomography (OCT) allows three-dimensional (3D) imaging of the retina, and is commonly used for assessing pathological changes of fovea and macula in many diseases. Many neuroinflammatory conditions are known to cause modifications to the fovea shape. In this paper, we propose a method for parametric modeling of the foveal shape. Our method exploits invariant features of the macula from OCT data and applies a cubic Bézier polynomial along with a least square optimization to produce a best fit parametric model of the fovea. Additionally, we provide several parameters of the foveal shape based on the proposed 3D parametric modeling. Our quantitative and visual results show that the proposed model is not only able to reconstruct important features from the foveal shape, but also produces less error compared to the state-of-the-art methods. Finally, we apply the model in a comparison of healthy control eyes and eyes from patients with neuroinflammatory central nervous system disorders and optic neuritis, and show that several derived model parameters show significant differences between the two groups.
Collapse
Affiliation(s)
- Sunil Kumar Yadav
- NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin,
Germany
- Mathematical Geometry Processing Group, Freie Universität Berlin,
Germany
| | | | - Timm Oberwahrenbrock
- NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin,
Germany
| | | | - Konrad Polthier
- Mathematical Geometry Processing Group, Freie Universität Berlin,
Germany
| | - Friedemann Paul
- NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin,
Germany
- Department of Neurology, Charité - Universitätsmedizin Berlin,
Germany
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin,
Germany
| | - Ella Maria Kadas
- NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin,
Germany
| | - Alexander U. Brandt
- NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin,
Germany
| |
Collapse
|
27
|
Tewarie P, Balk LJ, Hillebrand A, Steenwijk MD, Uitdehaag BMJ, Stam CJ, Petzold A. Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study. Ann Clin Transl Neurol 2017; 4:614-621. [PMID: 28904983 PMCID: PMC5590521 DOI: 10.1002/acn3.415] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Revised: 03/05/2017] [Accepted: 03/31/2017] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND We conducted a multi-modal optical coherence tomography (OCT) and magnetoencephalography (MEG) study to test whether there is a relationship between retinal layer integrity and electrophysiological activity and connectivity (FC) in the visual network influenced by optic neuritis (ON) in patients with multiple sclerosis (MS). METHODS One hundred and two MS patients were included in this MEG/OCT study. Retinal OCT data were collected from the optic discs, macular region, and segmented. Neuronal activity and FC in the visual cortex was estimated from source-reconstructed resting-state MEG data by computing relative power and the phase lag index (PLI). Generalized estimating equations (GEE) were used to account for intereye within-patient dependencies. RESULTS There was a significant relationship for both relative power and FC in the visual cortex with retinal layer thicknesses. The findings were influenced by the presence of MSON, particularly for connectivity in the alpha bands and the outer macular layers. In the absence of MSON, this relationship was dominated by the lower frequency bands (theta, delta) and inner and outer retinal layers. CONCLUSION These results suggest that visual cortex FC more than activity alters in the presence of MSON, which may guide the understanding of FC plasticity effects following MSON.
Collapse
Affiliation(s)
- Prejaas Tewarie
- Department of Neurology Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands.,Sir Peter Mansfield Imaging Centre School of Physics and Astronomy University of Nottingham Nottingham United Kingdom
| | - Lisanne J Balk
- Department of Neurology Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands
| | - Arjan Hillebrand
- Department of Clinical Neurophysiology and MEG Center Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands
| | - Martijn D Steenwijk
- Department of Neurology Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands.,Department of Anatomy and Neurosciences Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands
| | - Bernard M J Uitdehaag
- Department of Neurology Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands
| | - Cornelis J Stam
- Department of Clinical Neurophysiology and MEG Center Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands
| | - Axel Petzold
- Department of Neurology Neuroscience Campus Amsterdam VU University Medical Center Amsterdam Netherlands.,Department of Ophthalmology VU University Medical Center Amsterdam Netherlands.,Moorfields Eye Hospital City Road London United Kingdom
| |
Collapse
|
28
|
Britze J, Pihl-Jensen G, Frederiksen JL. Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol 2017; 264:1837-1853. [PMID: 28567539 DOI: 10.1007/s00415-017-8531-y] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 05/24/2017] [Accepted: 05/24/2017] [Indexed: 11/29/2022]
Abstract
The aim of this study was to summarise existing findings regarding optical coherence tomography (OCT) measurements of ganglion cell layer (GCL) alterations in optic neuritis (ON) and multiple sclerosis (MS). Peer-reviewed studies published prior to April 2016 were searched using PubMed, EMBASE, Web of Science and Scopus. Studies were included if they measured GCL thickness using OCT in patients with either ON, MS or clinically isolated syndrome. For the meta-analysis, we compared GCL thickness in MS patients with and without prior ON, to healthy controls. 42/252 studies were reviewed. In acute ON, studies showed significant thinning of the GCL within the first 5 weeks (n = 5), earlier than retinal nerve fibre layer (RNFL) thinning. GCL thinning at 1-2 months after acute ON predicted visual function at 6 months (n = 3). The meta-analysis showed that the thickness of the GCL was significantly reduced in MS patients both with and without previous ON compared to healthy controls. GCL thinning was associated with visual function in most studies (n = 10) and expanded disability status scale (EDSS) scores (n = 6). In acute ON, thinning of the GCL is measurable prior to RNFL thinning, and GCL thickness after 1-2 months may predict visual function after 6 months. Furthermore, GCL thinning occurs in MS both with and without prior ON, and may be associated with visual function and EDSS score. This suggests that the GCL is a promising biomarker, which may be used to examine in vivo neurodegeneration in ON and MS.
Collapse
Affiliation(s)
- Josefine Britze
- Department of Neurology, Clinic of Optic Neuritis and Clinic of Multiple Sclerosis, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, 2600, Glostrup, Denmark
| | - Gorm Pihl-Jensen
- Department of Neurology, Clinic of Optic Neuritis and Clinic of Multiple Sclerosis, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, 2600, Glostrup, Denmark
| | - Jette Lautrup Frederiksen
- Department of Neurology, Clinic of Optic Neuritis and Clinic of Multiple Sclerosis, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, 2600, Glostrup, Denmark.
| |
Collapse
|
29
|
Cilingir V, Batur M, Bulut MD, Milanlioglu A, Yılgor A, Batur A, Yasar T, Tombul T. The association between retinal nerve fibre layer thickness and corpus callosum index in different clinical subtypes of multiple sclerosis. Neurol Sci 2017; 38:1223-1232. [PMID: 28396954 DOI: 10.1007/s10072-017-2947-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 04/01/2017] [Indexed: 01/13/2023]
Abstract
The objective of this paper is to evaluate the association between physical disability in multiple sclerosis (MS) patients, the thickness of the retinal nerve fibre layer (RNFL) and corpus callosum volumes, as expressed by the corpus callosum index (CCI). This study was based on a cohort of 212 MS patients and 52 healthy control subjects, who were age and gender matched. The MS patients included 144 women and 177 relapsing-remitting MS (RRMS) patients. Peripapillary and volumetric optical coherence tomography (OCT) scans of the macula were performed using spectral-domain OCT technology. All magnetic resonance imaging (MRI) scans were performed using 1.5-T systems. CCI and RNFL were lower in MS than healthy control subjects (0.341 versus 0.386, p < 0.01 and 92.1 versus 105.0, p < 0.01). In addition, CCI correlated with RNFL (r = 0.464, p < 0.01). This was also true for the subgroup of patients with no history of optic neuritis (ON). There is a correlation between the thickness of the RNFL and CCI values in MS patients with no history of ON, which suggests that OCT might be a suitable marker for neurodegeneration in MS clinical trials.
Collapse
Affiliation(s)
- Vedat Cilingir
- Faculty of Medicine Neurology Department, Yuzuncu Yil University, 65000, Kampus Van, Turkey.
| | - Muhammed Batur
- Faculty of Medicine Ophthalmology Department, Yuzuncu Yil University, Van, Turkey
| | - Mehmet Deniz Bulut
- Faculty of Medicine Radiology Department, Yuzuncu Yil University, Van, Turkey
| | - Aysel Milanlioglu
- Faculty of Medicine Neurology Department, Yuzuncu Yil University, 65000, Kampus Van, Turkey
| | - Abdullah Yılgor
- Faculty of Medicine Neurology Department, Yuzuncu Yil University, 65000, Kampus Van, Turkey
| | - Abdussamet Batur
- Faculty of Medicine Radiology Department, Yuzuncu Yil University, Van, Turkey
| | - Tekin Yasar
- Faculty of Medicine Ophthalmology Department, Yuzuncu Yil University, Van, Turkey
| | - Temel Tombul
- Faculty of Medicine Neurology Department, Yuzuncu Yil University, 65000, Kampus Van, Turkey
| |
Collapse
|
30
|
Behbehani R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, Oakley JD, Alroughani R. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One 2017; 12:e0172120. [PMID: 28192539 PMCID: PMC5305239 DOI: 10.1371/journal.pone.0172120] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2016] [Accepted: 01/31/2017] [Indexed: 01/21/2023] Open
Abstract
Introduction Optical coherence tomography (OCT) with retinal segmentation analysis is a valuable tool in assessing axonal loss and neuro-degeneration in multiple sclerosis (MS) by in-vivo imaging, delineation and quantification of retinal layers. There is evidence of deep retinal involvement in MS beyond the inner retinal layers. The ultra-structural retinal changes in MS in different MS phenotypes can reflect differences in the pathophysiologic mechanisms. There is limited data on the pattern of deeper retinal layer involvement in progressive MS (PMS) versus relapsing remitting MS (RRMS). We have compared the OCT segmentation analysis in patients with relapsing-remitting MS and progressive MS. Methods Cross-sectional study of 113 MS patients (226 eyes) (29 PMS, 84 RRMS) and 38 healthy controls (72 eyes). Spectral domain OCT (SDOCT) using the macular cube acquisition protocol (Cirrus HDOCT 5000; Carl Zeiss Meditec) and segmentation of the retinal layers for quantifying the thicknesses of the retinal layers. Segmentation of the retinal layers was carried out utilizing Orion software (Voxeleron, USA) for quantifying the thicknesses of individual retinal layers. Results The retinal nerve finer layer (RNFL) (p = 0.023), the ganglion-cell/inner plexiform layer (GCIPL) (p = 0.006) and the outer plexiform layer (OPL) (p = 0.033) were significantly thinner in PMS compared to RRMS. There was significant negative correlation between the outer nuclear layer (ONL) and EDSS (r = -0.554, p = 0.02) in PMS patients. In RRMS patients with prior optic neuritis, the GCIPL correlated negatively (r = -0.317; p = 0.046), while the photoreceptor layer (PR) correlated positively with EDSS (r = 0.478; p = 0.003). Conclusions Patients with PMS exhibit more atrophy of both the inner and outer retinal layers than RRMS. The ONL in PMS and the GCIPL and PR in RRMS can serve as potential surrogate of disease burden and progression (EDSS). The specific retinal layer predilection and its correlation with disability may reflect different pathophysiologic mechanisms and various stages of progression in MS.
Collapse
Affiliation(s)
- Raed Behbehani
- Al-Bahar Ophthalmology Center, Ibn Sina Hospital, Kuwait City, Kuwait
- Neurology Clinic, Dasman Institute, Dasman, Kuwait
- * E-mail:
| | | | - Ali Al-Salahat
- Al-Bahar Ophthalmology Center, Ibn Sina Hospital, Kuwait City, Kuwait
| | | | - J. D. Oakley
- Voxeleron LLC, Pleasanton, CA, United States of America
| | - Raed Alroughani
- Neurology Clinic, Dasman Institute, Dasman, Kuwait
- Division of Neurology, Amiri Hospital, Sharq, Kuwait
| |
Collapse
|
31
|
Soltys J, Wang Q, Mao-Draayer Y. Optical coherence tomography and T cell gene expression analysis in patients with benign multiple sclerosis. Neural Regen Res 2017; 12:1352-1356. [PMID: 28966652 PMCID: PMC5607832 DOI: 10.4103/1673-5374.213558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Benign multiple sclerosis is a retrospective diagnosis based primarily on a lack of motor symptom progression. Recent findings that suggest patients with benign multiple sclerosis experience non-motor symptoms highlight the need for a more prospective means to diagnose benign multiple sclerosis early in order to help direct patient care. In this study, we present optical coherence tomography and T cell neurotrophin gene analysis findings in a small number of patients with benign multiple sclerosis. Our results demonstrated that retinal nerve fiber layer was mildly thinned, and T cells had a distinct gene expression profile that included upregulation of interleukin 10 and leukemia inhibitory factor, downregulation of interleukin 6 and neurotensin high affinity receptor 1 (a novel neurotrophin receptor). These findings add evidence for further investigation into optical coherence tomography and mRNA profiling in larger cohorts as a potential means to diagnose benign multiple sclerosis in a more prospective manner.
Collapse
Affiliation(s)
- John Soltys
- Present Address: University of Colorado Medical Scientist Training Program (MSTP), Aurora, CO, USA
| | - Qin Wang
- Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Yang Mao-Draayer
- Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA
| |
Collapse
|
32
|
Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 2016; 86:2303-9. [PMID: 27225223 PMCID: PMC4909557 DOI: 10.1212/wnl.0000000000002774] [Citation(s) in RCA: 314] [Impact Index Per Article: 39.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 03/14/2016] [Indexed: 01/01/2023] Open
Abstract
Objective: To develop consensus recommendations for reporting of quantitative optical coherence tomography (OCT) study results. Methods: A panel of experienced OCT researchers (including 11 neurologists, 2 ophthalmologists, and 2 neuroscientists) discussed requirements for performing and reporting quantitative analyses of retinal morphology and developed a list of initial recommendations based on experience and previous studies. The list of recommendations was subsequently revised during several meetings of the coordinating group. Results: We provide a 9-point checklist encompassing aspects deemed relevant when reporting quantitative OCT studies. The areas covered are study protocol, acquisition device, acquisition settings, scanning protocol, funduscopic imaging, postacquisition data selection, postacquisition data analysis, recommended nomenclature, and statistical analysis. Conclusions: The Advised Protocol for OCT Study Terminology and Elements recommendations include core items to standardize and improve quality of reporting in quantitative OCT studies. The recommendations will make reporting of quantitative OCT studies more consistent and in line with existing standards for reporting research in other biomedical areas. The recommendations originated from expert consensus and thus represent Class IV evidence. They will need to be regularly adjusted according to new insights and practices.
Collapse
Affiliation(s)
- Andrés Cruz-Herranz
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Lisanne J Balk
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Timm Oberwahrenbrock
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Shiv Saidha
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Elena H Martinez-Lapiscina
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Wolf A Lagreze
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Joel S Schuman
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Pablo Villoslada
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Peter Calabresi
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Laura Balcer
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Axel Petzold
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Ari J Green
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Friedemann Paul
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Alexander U Brandt
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany
| | - Philipp Albrecht
- From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité-Universitätsmedizin Berlin (T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University, Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Germany.
| | | |
Collapse
|
33
|
Oberwahrenbrock T, Weinhold M, Mikolajczak J, Zimmermann H, Paul F, Beckers I, Brandt AU. Reliability of Intra-Retinal Layer Thickness Estimates. PLoS One 2015; 10:e0137316. [PMID: 26349053 PMCID: PMC4562656 DOI: 10.1371/journal.pone.0137316] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Accepted: 08/15/2015] [Indexed: 12/15/2022] Open
Abstract
PURPOSE Measurement of intra-retinal layer thickness using optical coherence tomography (OCT) has become increasingly prominent in multiple sclerosis (MS) research. Nevertheless, the approaches used for determining the mean layer thicknesses vary greatly. Insufficient data exist on the reliability of different thickness estimates, which is crucial for their application in clinical studies. This study addresses this lack by evaluating the repeatability of different thickness estimates. METHODS Studies that used intra-retinal layer segmentation of macular OCT scans in patients with MS were retrieved from PubMed. To investigate the repeatability of previously applied layer estimation approaches, we generated datasets of repeating measurements of 15 healthy subjects and 13 multiple sclerosis patients using two OCT devices (Cirrus HD-OCT and Spectralis SD-OCT). We calculated each thickness estimate in each repeated session and analyzed repeatability using intra-class correlation coefficients and coefficients of repeatability. RESULTS We identified 27 articles, eleven of them used the Spectralis SD-OCT, nine Cirrus HD-OCT, two studies used both devices and two studies applied RTVue-100. Topcon OCT-1000, Stratus OCT and a research device were used in one study each. In the studies that used the Spectralis, ten different thickness estimates were identified, while thickness estimates of the Cirrus OCT were based on two different scan settings. In the simulation dataset, thickness estimates averaging larger areas showed an excellent repeatability for all retinal layers except the outer plexiform layer (OPL). CONCLUSIONS Given the good reliability, the thickness estimate of the 6mm-diameter area around the fovea should be favored when OCT is used in clinical research. Assessment of the OPL was weak in general and needs further investigation before OPL thickness can be used as a reliable parameter.
Collapse
Affiliation(s)
- Timm Oberwahrenbrock
- NeuroCure Clinical Research Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
- * E-mail:
| | - Maria Weinhold
- Optics and Laser Technology Laboratory, Beuth University of Applied Sciences, Berlin, Germany
| | - Janine Mikolajczak
- NeuroCure Clinical Research Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
| | - Hanna Zimmermann
- NeuroCure Clinical Research Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
| | - Friedemann Paul
- NeuroCure Clinical Research Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Charité–Universitätsmedizin, Berlin, Germany
| | - Ingeborg Beckers
- Optics and Laser Technology Laboratory, Beuth University of Applied Sciences, Berlin, Germany
| | - Alexander U. Brandt
- NeuroCure Clinical Research Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
34
|
Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BMJ, Petzold A. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015; 86:419-24. [PMID: 24973342 DOI: 10.1136/jnnp-2014-308189] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OBJECTIVE To investigate the coexistence of anterograde and retrograde trans-synaptic axonal degeneration, and to explore the relationship between selective visual pathway damage and global brain involvement in longstanding multiple sclerosis (MS). METHODS In this single-centre, cross-sectional study, patients with longstanding MS (N=222) and healthy controls (HC, N=62) were included. We analysed thickness of retinal layers (optical coherence tomography), damage within optic radiations (OR) (lesion volume and fractional anisotropy and mean diffusivity by diffusion tensor imaging) and atrophy of the visual cortex and that of grey and white matter of the whole-brain (structural MRI). Linear regression analyses were used to assess associations between the different components and for comparing patients with and without optic neuritis and HC. RESULTS In patients with MS, an episode of optic neuritis (MSON) was significantly associated with decreased integrity of the ORs and thinning of the peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell complex (GCC). Lesion volume in the OR was negatively associated with pRNFL and GCC thickness in patients without optic neuritis (MSNON). The pRNFL and GCC showed associations with integrity of the OR, thickness of the primary visual cortex (only in patients with MSON), and also with global white and grey matter atrophy. In HCs, no such relationships were demonstrated. INTERPRETATION This study provides evidence for presence of bidirectional (both anterograde and retrograde) trans-synaptic axonal degeneration in the visual pathway of patients with MS. Additionally, thinning of the retinal pRNFL and GCC are related to global white and grey matter atrophy in addition to pathology of the visual pathway.
Collapse
Affiliation(s)
- L J Balk
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - M D Steenwijk
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - P Tewarie
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - M Daams
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands Department of Anatomy and Neurosciences, Section of Clinical Neuroscience, VU University Medical Center, Amsterdam, The Netherlands
| | - J Killestein
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - M P Wattjes
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - H Vrenken
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands
| | - F Barkhof
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - C H Polman
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - B M J Uitdehaag
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - A Petzold
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
35
|
Petzold A, Nijland PG, Balk LJ, Amorini AM, Lazzarino G, Wattjes MP, Gasperini C, van der Valk P, Tavazzi B, Lazzarino G, van Horssen J. Visual pathway neurodegeneration winged by mitochondrial dysfunction. Ann Clin Transl Neurol 2014; 2:140-50. [PMID: 25750919 PMCID: PMC4338955 DOI: 10.1002/acn3.157] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Revised: 10/29/2014] [Accepted: 11/16/2014] [Indexed: 12/12/2022] Open
Abstract
Objectives To test for structural and functional contribution of mitochondrial dysfunction to neurodegeneration in multiple sclerosis (MS). A visual pathway model void of MS lesions was chosen in order to exclude neurodegeneration secondary to lesion related axonotmesis. Methods A single-centre cohort study (230 MS patients, 63 controls). Spectral domain optical coherence tomography of the retina, 3T magnetic resonance imaging of the brain, spectrophotometric assessment of serum lactate levels. Postmortem immunohistochemistry. Results The visual pathway was void of MS lesions in 31 patients and 31 age-matched controls. Serum lactate was higher in MS compared to controls (P = 0.029). High serum lactate was structurally related to atrophy of the retinal nerve fiber layer at the optic disc (P = 0.041), macula (P = 0.025), and the macular ganglion cell complex (P = 0.041). High serum lactate was functionally related to poor color vision (P < 0.01), Expanded Disability Status Scale score (R = 0.37, P = 0.041), Guy's Neurological disability score (R = 0.38, P = 0.037), MS walking scale (R = 0.50, P = 0.009), upper limb motor function (R = 0.53, P = 0.002). Immunohistochemistry demonstrated increased astrocytic expression of a key lactate generating enzyme in MS lesions as well as profound vascular expression of monocarboxylate transporter-1, which is involved in lactate transport. Interpretation This study provides structural, functional, and translational evidence for visual pathway neurodegeneration in MS related to mitochondrial dysfunction.
Collapse
Affiliation(s)
- Axel Petzold
- Department of Neurology, VU University Medical Center De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands ; Department of Ophthalmology, VU University Medical Center De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands ; Molecular Neuroscience, UCL Institute of Neurology Queen Square, London, WC1N 3BG, United Kingdom ; Moorfields Eye Hospital, Neuro-ophthalmology City Road, London, UK
| | - Philip G Nijland
- Department of Pathology, VU University Medical Center Amsterdam, The Netherlands
| | - Lisanne J Balk
- Department of Neurology, VU University Medical Center De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Angela Maria Amorini
- Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome Largo F. Vito 1, 00168, Rome, Italy
| | - Giacomo Lazzarino
- Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome Largo F. Vito 1, 00168, Rome, Italy
| | - Mike P Wattjes
- Department of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, The Netherlands
| | - Claudio Gasperini
- Department of Neurosciences, S Camillo Forlanini Hospital Circonvallazione Gianicolense 87, 00152, Rome, Italy
| | - Paul van der Valk
- Department of Pathology, VU University Medical Center Amsterdam, The Netherlands
| | - Barbara Tavazzi
- Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome Largo F. Vito 1, 00168, Rome, Italy
| | - Giuseppe Lazzarino
- Division of Biochemistry and Molecular Biology, Department of Biology, Geology and Environmental Sciences, University of Catania Viale A. Doria 6, 95125, Catania, Italy
| | - Jack van Horssen
- Molecular Cell Biology and Immunology, VU University Medical Center Amsterdam, The Netherlands
| |
Collapse
|
36
|
Re: Garcia-Martin et al.: Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography (Ophthalmology 2014;121:573-9). Ophthalmology 2014; 121:e63. [PMID: 25444947 DOI: 10.1016/j.ophtha.2014.06.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 06/12/2014] [Indexed: 11/20/2022] Open
|
37
|
Hutchinson M. Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: commentary. Mult Scler 2014; 20:1302-3. [PMID: 25160124 DOI: 10.1177/1352458514545144] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Buckow K, Quade M, Rienhoff O, Nussbeck SY. Changing requirements and resulting needs for IT-infrastructure for longitudinal research in the neurosciences. Neurosci Res 2014; 102:22-8. [PMID: 25152316 DOI: 10.1016/j.neures.2014.08.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 08/06/2014] [Accepted: 08/13/2014] [Indexed: 11/18/2022]
Abstract
The observation of growing "difficulties" in IT-infrastructures in neuroscience research during the last years led to a search for reasons and an analysis on how this phenomenon is reflected in the scientific literature. With a retrospective analysis of nine examples of multicenter research projects in the neurosciences and a literature review the observation was systematically analyzed. Results show that the rise in complexity mainly stems from two reasons: (1) more and more need for information on quality and context of research data (metadata) and (2) long-term requirements to handle the consent and identity/pseudonyms of study participants and biomaterials in relation to legal requirements. The combination of these two aspects together with very long study times and data evaluation periods are components of the subjectively perceived "difficulties". A direct consequence of this result is that big multicenter trials are becoming part of integrated research data environments and are not standing alone for themselves anymore. This drives up the resource needs regarding the IT-infrastructure in neuroscience research. In contrast to these findings, literature on this development is scarce and the problem probably underestimated.
Collapse
Affiliation(s)
- Karoline Buckow
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany
| | - Matthias Quade
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany
| | - Otto Rienhoff
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany
| | - Sara Y Nussbeck
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
| |
Collapse
|
39
|
Balk LJ, Petzold A. Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis. Neurodegener Dis Manag 2014; 4:165-76. [DOI: 10.2217/nmt.14.10] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
SUMMARY Multiple sclerosis (MS) is a disorder characterized by inflammation and neuroaxonal degeneration. The latter is held responsible for the irreversible disability in patients with MS. The eye is a unique window into the brain. With the advent of optical coherence tomography, accurate quantification of retinal layer thickness has become feasible. Neuroaxonal degeneration affecting the retinal layers is structurally and functionally related to pathology in the visual pathways, which is most severe following MS optic neuritis. This is relevant to recognize because MS optic neuritis may mask the subtle thinning of retinal layers associated with global CNS atrophy, which is also related to more global loss of neurological function. Taken together, optical coherence tomography stands at the brink of becoming a validated imaging biomarker for monitoring neurodegeneration in MS and to provide end points for clinical trials.
Collapse
Affiliation(s)
- Lisanne J Balk
- Department of Neurology, VU Medical Centre Amsterdam, Amsterdam, The Netherlands
| | - Axel Petzold
- Department of Neurology, VU Medical Centre Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|